News

Deal Announcements

Apellis Pharma Accepts $32 Million Equity VC

Thursday, January 7, 2016 5:17:00 AM PDT | VentureDeal
   Crestwood, Kentucky  --  Apellis Pharmaceuticals has secured $32.1 million in new equity venture capital investment, according to an SEC regulatory filing.

Apellis is an early stage drug development company focused on peptide drugs in the immunology space.

Investors in the financing were not disclosed, nor was how the company intends to use the proceeds.

A total of six investors participated in the offering.

Apellis was founded in January 2010 by President and CEO Cedric François.

Email Page  Email Page | Print Page Print Page

Free Trial

Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?

Start your Free 14 Day Trial now – no obligation or credit card required.

Free 14 day trial. No Obligation. Click to Register.
Venturedeal Twitter Venturedeal Facebook Venturedeal Linkedin


PCI - Level1